HBSP (USA)
-
BASF: Co-Creating Innovation (A)
Rangan, V. Kasturi; Billaud, Emilie; Dessain, VincentCase HBS-517073-EIn 2016, BASF's Chief Executive Officer and Chief Technology Officer reflected on the co-creation innovation program started almost 18 months ago as part of BASF's 150th anniversary celebration. 500 project ideas had been created, of which 100 had already moved to the company's conventional R&D funnel. 34 had been short-listed for further consideration. At least 10, if not more of these projects would receive "landmark" funding running at an aver...Starting at €8.20
-
BASF: Co-Creating Innovation (B)
Rangan, V. Kasturi; Billaud, Emilie; Dessain, VincentCase HBS-517074-EMarketingSupplement to case 517073.Starting at €5.74
-
Global Knowledge Management at Danone (A)
Edmondson, Amy C.; Moingeon, Bertrand; Dessain, Vincent; Jensen, Ane DamgaardCase HBS-608107-EKnowledge and CommunicationThis case explores French consumer goods company Danone's novel approach to knowledge management. In 2007, Human Resource Chief (Executive Vice President) Franck Mougin assesses the company's knowledge-sharing tools and considers his options going Forward. Through informal knowledge marketplaces and sharing networks, Danone had helped managers connect with each other and share good practices peer-to-peer, rather than relying on traditional hierar...Starting at €8.20
-
China: "To Get Rich Is Glorious," Teaching Note
Vietor, Richard H.K.; Dessain, VincentTeaching Note HBS-708008-EEconomicsTeaching Note to 707022.Starting at €0.00
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCase HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Starting at €8.20
-
Preserve the Luxury or Extend the Brand (Commentary for HBR Case Study)
Beyersdorfer, Daniela; Dessain, VincentArticle HBS-R1101Z-EMarketingMany luxury brands are able to command high prices because of their excellent quality, solid reputation, and limited availability. But it can be tricky both to maintain that cachet and continue to grow if the next generation of consumers is completely priced out of your market. Fictional winemaker Chateau de Vallois, a traditional estate with centuries of experience in producing luxury wines, faces that dilemma and is now considering whether to l...Starting at €8.20
-
Bonuses in Bad Times (Commentary for HBR Case Study)
Beyersdorfer, Daniela; Dessain, Vincent; Ton, ZeynepArticle HBS-R1207Z-ELeadership and People ManagementIt's 2008 and Spanish food retailer Superado is on course to miss its financial targets. According to company policy, this means that Superado should withhold all bonuses for the year. But the company has an unbroken tradition of paying out bonuses and treating its workforce well--and it enjoys low staff turnover and high productivity as a result. In this fictionalized case study, based on a Harvard Business School case by Zeynep Ton and Simon Ha...Starting at €8.20
-
Ilva Steel Taranto: Providing and Polluting (B)
Goldberg, Lena G.; Dessain, Vincent; Pesce, Ottavia; Misztal, KarolCase HBS-314058-EStarting at €5.74
-
The Novartis Malaria Initiative
Chu, Michael; Dessain, Vincent; Billaud, EmilieCase HBS-314103-EBusiness Ethics and Corporate Social ResponsibilityThe Novartis Malaria Initiative was designed, as a result of a precedent-setting agreement with the World Health Organization in 2001, to provide a breakthrough treatment for malaria-"at no profit"-for public health systems. What had begun as an exemplary act of corporate responsibility had succeeded beyond any expectations. In 2012, for the second year in a row, Novartis had manufactured and distributed over 100 million units of the anti-malaria...Starting at €8.20
-
Go Beyond Investing
Applegate, Lynda M.; Dessain, Vincent; Billaud, Emilie; Beyersdorfer, DanielaCase HBS-814046-EEntrepreneurshipIn 2013, Brigitte Baumann, founder of the Pan-European angel investing provider Go Beyond Investing, reflected on the evolution of her venture and the way forward. Her company, which offered deal flow and training to novice and experienced angel investors and ran investor groups in several European countries, had reached a critical size, and Baumann needed to make a strategic decision to ensure its future growth in an industry that was undergoing...Starting at €8.20